• Spermosens launched a Generation 3 clinical validation study for its JUNO-Checked fertility test in April–June 2026.
• Results have not been presented yet; completion remains targeted for end-2026, with recruitment resuming in mid-August.
• Early study execution indicates the system is easy to use, with consistent performance in the clinical setting.
• Recruitment outpaced internal expectations, reaching 44 patients before the summer break at the Malmö study site.
• A SEK 4.85 million capital facility was secured to fund study completion, supporting licensing-focused commercial partner talks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spermosens AB published the original content used to generate this news brief via Cision (Ref. ID: 202608200258BITN____UKPR__EN_20260820-BIT-9971-0) on August 20, 2026, and is solely responsible for the information contained therein.